Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, the air detected in capiox.As per the user facility, incident occurred on bypass.Air was removed with short delay in procedure.No blood loss reported.Oxygenator was saved and flushed out with water to be inspected by terumo.There was an unknown minutes of delay.Product was not changed out.Procedure was completed successfully.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on april 12, 2024.Upon further investigation of the reported event, the following information is new and/or changed: b5 (updated describe event or problem) d9 (device availability - added date returned to manufacturer) g3 (date received by manufacturer) g6 (indication that this is a follow-up report) h2 (follow-up due to additional information) h3 (evaluation is in progress, but not yet concluded, thus code 81) a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11.) all available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|